The AGGF1 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered for targeted gene disruption of AGGF1 within the HT29 human colorectal adenocarcinoma host cell line. This loss-of-function model provides a versatile tool for investigating AGGF1-dependent angiogenic signaling and its role in colorectal cancer biology. The polyclonal population, generated through CRISPR/Cas9-mediated gene editing, retains genetic heterogeneity while eliminating AGGF1 expression, enabling robust functional studies without the selection bias of single-cell clones.
The host cell line HT29 is a well-established human colorectal adenocarcinoma model isolated from a primary tumor. These adherent epithelial cells exhibit characteristics of intestinal epithelial cells and are widely used in studies of colorectal cancer, intestinal barrier function, and enterocytic differentiation. HT29 cells have been instrumental in dissecting signaling pathways driving tumorigenesis, metastasis, and tumor microenvironment interactions, making them an appropriate platform for interrogating the angiogenic contributions of AGGF1.
AGGF1, or angiogenic factor with G patch and FHA domains 1, is a key pro-angiogenic protein that promotes endothelial cell proliferation, migration, and tube formation through activation of the PI3K-Akt and MAPK/ERK pathways. Upstream regulators include hypoxia-inducible factor 1?? (HIF-1??) and vascular endothelial growth factor (VEGF), while downstream targets encompass Akt, ERK1/2, and endothelial nitric oxide synthase (eNOS). AGGF1 functionally interacts with ALK1, SMAD1/5, ??-catenin, and Endoglin, integrating signals from TGF-?? and Wnt pathways to modulate angiogenic responses. Representative pathway components such as VEGFR2, PI3K, mTOR, and HIF-1?? further delineate its signaling network.
In the context of HT29 colorectal cancer cells, AGGF1 knockout is anticipated to disrupt angiogenic signaling that supports tumor growth. HT29 cells express VEGF and are responsive to hypoxic conditions, paralleling the tumor microenvironment where AGGF1 orchestrates cross-talk between cancer cells and endothelial cells. Disabling AGGF1 in these cells provides a system to dissect how tumor-derived angiogenic factors influence vascular development and to evaluate the consequent effects on cancer cell behavior, including proliferation and survival under stress conditions.
Typical applications of these polyclonal knockout cells include angiogenesis research, colorectal cancer studies, and drug screening for anti-angiogenic therapies. Researchers can employ Western blotting and RT-qPCR to confirm knockout and analyze downstream signaling components such as phospho-Akt and phospho-ERK. Functional assays like tube formation using conditioned media from knockout cells, migration and proliferation assays, and xenograft tumor growth models are suitable for assessing angiogenic potential. Immunofluorescence can visualize protein localization and endothelial cell interactions. For further information, please contact Ascent Research.
